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Abstract
Background: Immunoglobulin κ and λ free light chains 
(FLC) are important serum biomarkers for diagnosing 
and monitoring plasma cell dyscrasias (via the κ:λ FLC 
ratio), and assessing immune competence and activa-
tion status (via ∑FLC). FLCs are produced, in excess of 
heavy chains, from healthy plasma cells during immuno-
globulin production, but unlike intact immunoglobulins 
that are cleared by cellular catabolism over a number of 
weeks, FLC are rapidly cleared from the bloodstream by 
the renal glomerulus with a half-life of 3 (κ FLC)–6 (λ FLC) 
hours. Marathon running has been shown to acutely and 
transiently decrease renal function, however, the impact 
of prolonged aerobic exercise on FLC levels remains 
unknown.
Methods: We measured serum FLC levels in 60 runners 
before, and immediately after, the 2010 Eindhoven 
Marathon.
Results: A significant increase (p < 0.01) in κ FLC levels 
was observed after the marathon, and κ FLC correlated 
positively with serum creatinine levels. No changes were 
observed for λ FLC, and thus, there were subtle elevations 
in the ∑FLC and FLC ratio in some participants. Indeed, 
we found that 13% of participants had an abnormally 
increased FLC ratio upon completion of the marathon; a 
phenomenon previously observed in renal diseases.
Conclusions: Abnormal FLC ratios observed after exer-
cise reflected an increase in serum κ FLC levels, which 
may be due to acute and transient reductions in renal 
function during exercise, though we also observed an 
increase in serum IgG and IgA and thus cannot exclude 
exercise-induced immune stimulation or immunoglobulin 
redistribution.
Keywords: exercise; free light chains; immunoglobulins; 
renal function.
Introduction
Over the last decade, serum immunoglobulin free κ and λ 
light chains (FLC) have become a pivotal haematological 
biomarker for the screening and monitoring of plasma cell 
dyscrasias. FLCs are important for diagnosing, monitoring 
and prognosticating multiple myeloma, monoclonal gam-
mopathy of unknown significance (MGUS) and an array 
of other associated disorders [1]. More recently, the prog-
nostic utility of FLCs in non-neoplastic disorders has been 
highlighted [2–4]. Moreover, the sum of polyclonal κ and 
λ FLCs, expressed as ∑FLC, has been advocated as a global 
biomarker of immune activation [5], and is now regarded 
as a powerful prognostic marker for overall survival in the 
general population [6].
Additionally, FLCs are considered a more accurate ‘real 
time’ indicator of immune activation than intact immuno-
globulins. This is because, unlike intact  immunoglobulins 
that are cleared by cellular catabolism and have a rela-
tively long half-life extending from 1 (IgA, IgM) to 3 weeks 
(IgG), FLCs are cleared from the bloodstream by the renal 
glomeruli and metabolised in the proximal tubules of 
the nephrons and have a considerably shorter half-life. κ 
FLCs, which are typically present in the bloodstream as 
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monomers, have a half-life of 2–3 h, whereas λ FLC, which 
are typically dimerised have a longer half-life of 4–6 h. 
Thus, as a consequence of renal impairment, serum FLC 
are elevated and positively correlate with creatinine, cys-
tatin-C and kidney disease staging [7].
Marathon running has been shown to induce a 
transient decrease in renal function evocative of acute 
kidney injury [8]. In the aforementioned study, it was 
shown that serum creatinine levels – supported by raised 
cystatin-C and urine biomarkers symptomatic of kidney 
injury – were elevated in nearly half of the participants 
who completed the marathon [8]. To date, the impact 
of aerobic exercise on FLC levels remains unknown. 
We recently investigated the effects of long duration 
walking exercise on FLC levels in the bloodstream of 
37 elderly participants [9]. Long duration walking exer-
cise did not significantly influence FLC levels, which is 
in line with the rationale that the physiological nature 
of walking exercise is not as likely to induce transient 
declines in renal function, as seen in marathon running 
[8]. Thus, it remains unknown how strenuous exercise 
affects κ FLC, λ FLC and ∑FLC levels, and whether acute 
alterations in kidney function during prolonged exercise 
affect the FLC ratio – a sensitive barometer of plasma 
cell neoplasm.
Thus, the aim of this study was to assess the effects of 
intensive aerobic exercise on κ FLC, λ FLC, ∑FLC and the 
FLC ratio. We hypothesised that previously reported acute 
and transient reductions in renal function during exercise 
[8], would result in an elevation in serum κ FLC, λ FLC 
and ∑FLC levels. As κ FLC are secreted by twice as many 
plasma cells as λ FLC, we hypothesised that a decline in 
renal clearance would increase the FLC ratio – as observed 
in renal disorders [7].
Materials and methods
Ninety-two moderately-to-highly trained runners (26–71  years of 
age) participated in the 2010 Eindhoven Marathon, as previously 
described [10]. Participants were recruited through the Eindhoven 
Marathons website, where an advertisement was placed prior to the 
event. Before participation, all participants provided informed con-
sent and the Medical Ethical Committee of the Radboud University 
Medical Center approved the study which was conducted in line with 
the declaration of Helsinki.
All participants completed an online questionnaire about 
subject characteristics, including daily physical activity, marathon 
experience (e.g. previous completed marathons, personal best) 
and health (e.g. medical history and medication use). On the day 
of the marathon, participants underwent a series of measurements 
in our laboratory situated adjacent to the marathon start and finish 
area. After collecting demographic data, a venous blood sample was 
taken. In addition, heart rate was monitored continuously during 
the race using a chest band. Immediately after completion of the 
marathon ( < 5 min after exercise cessation), all measurements were 
re-taken. Finally, all participants reported their individual fluid 
intake, use of analgesics, physical complaints and rating of per-
ceived exertion.
Ten millilitres of blood was drawn from an antecubital vein 
before and after the race. Whole venous blood was collected in a 
serum-gel vacutainer and allowed to clot for approximately 45 min 
before centrifugation. Serum was aliquoted and stored at −80 °C for 
later analysis.
Serum FLCs were measured on two established assays: a com-
mercially available latex assay on the Roche Hitachi Modular utilis-
ing polyclonal antibodies (Freelite®, The Binding Site, Birmingham, 
UK), and an in-house multi-plex Luminex® assay utilising mono-
clonal antibodies (Abingdon Health Ltd©, Oxford, UK) as described 
previously [11]. Briefly, mouse anti-human FLC κ (clone # BUCIS 04) 
and anti-FLC λ (clone # BUCIS 09) monoclonal antibodies (Abing-
don Health™) were covalently coupled to polystyrene Xmap® 
microspheres (BioRad, Hercules, CA, USA) and incubated – in a com-
petitive inhibition format – with patient sera and biotinylated FLC. 
After appropriate wash steps to remove unbound FLC, streptavidin-
rPhycoerythrin was then added before measurement on a Luminex® 
instrument where the fluorescent signal intensity was inversely cor-
related with κ or λ FLC concentration. The assay has good sensitivity 
and reproducibility, and correlates well with Freelite®™ (The Binding 
Site™) for polyclonal FLC [11]. In addition to FLCs, we also measured 
serum creatinine, IgG, IgA and IgM on a Roche Hitachi Modular. To 
minimise variation all Roche Hitachi Modular analyses were per-
formed on a single day using the same calibration set-up, batches, 
and user.
Heart rate during the marathon was measured in 70 participants 
using a two-channel electrocardiograph (ECG) chest band system 
(Polar Electro Oy, Kempele, Finland). Mean heart rate (HRmean) was 
determined as the average heart rate between the start and finish of 
the marathon, Maximal predicted heart rate (HRmax = 208–0.7*age) 
and exercise intensity (Ex Int = 100*HRmean/HRmax) were calcu-
lated subsequently [12]. Exercise duration (start time – finish time) 
was obtained using the ChampionChip time registration (Champion-
Chip, MYLAPS, The Netherlands), from which mean running speed 
was calculated (Speed = 42.195/exercise duration). After the mara-
thon, participants completed a questionnaire indicating analgesic 
use and physical complaints. A visual analogue scale was used to 
measure rating of perceived exertion.
Participants were allowed to drink ad libitum during the mara-
thon, but registered the time and amount (standard sized cups or 
bottles) of their individual fluid intake after the finish. An additional 
2 mL of blood was drawn at baseline and directly after finishing to 
determine plasma levels of haematocrit (Hct) and haemoglobin (Hb) 
(RapidLab® 1265, Siemens Healthcare Diagnostics Inc., Tarrytown, 
NY, USA). In accordance with the method of Dill and Costill [13], Hct 
and Hb were used to assess plasma volume changes (PVC) as a proxy 
indicator of serum protein concentration changes due to exercise-
induced dehydration. The equation is as follows:
Hb baseline Hb baseline100 Hct exercise ( 100 Hct baseline)
Hb exercise Hb exercis
% PVC
e
( 100 Hct baseline)
=
× − × − −
−
            
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resulted in a significant increase in serum creatinine from 
baseline to post-exercise (F(1, 59) = 220.026, p < 0.001), and 
this finding was maintained upon inclusion of PVCs as a 
covariate (F(1, 59) = 11.312, p = 0.002). Using the Acute Kidney 
Injury Network (AKIN) guidelines, we found that 42% of 
participants achieved AKI Stage 1, defined as a 50% rise in 
creatinine [14]. The percentage increase in creatinine from 
pre-marathon to post-marathon positively correlated with 
average exercise intensity (R2 = 0.375; p = 0.007; n = 60) and 
average heart rate (R2 = 0.367; p = 0.009; n = 60), but not race 
finish time or race speed (p > 0.05).
Serum FLC screening
Before assessing the effects of exercise on serum FLC 
levels, we first screened serum FLC results from all par-
ticipants at baseline to exclude those with abnormal abso-
lute κ and λ FLC levels which may be indicative of MGUS, 
immune stimulation or suppression, or renal impairment. 
To do this, we used the obtained Freelite® results, as the 
normal range for Freelite® is well established in the litera-
ture and is defined as 3.3–19.4 for κ FLC mg/L, 5.7–26.3 for λ 
FLC mg/L, and 0.26–1.65 for the FLC ratio [15]. At baseline, 
we found that nine of the 69 (12%) participants had an 
abnormal FLC ratio determined by Freelite®; these partici-
pants had no fundamental demographic or exercise physi-
ological differences to those with a normal FLC ratio. Upon 
further investigation, three of the nine participants had a 
λ FLC result below the initial range of Freelite® sensitivity, 
i.e. located below the well characterised limit of detection 
PVC data was available for 39 participants; exact n for all PVC 
analyses is reflected in the reported degrees of freedom for each 
analysis.
Statistical analyses were performed using the Statisti-
cal Package for the Social Sciences (SPSS Version 21, IBM Corp., 
Armonk, NY, USA). All data were reported as mean±SD unless 
stated otherwise, and statistical significance was assumed at a 
p-value  < 0.05. All data were normally distributed, as determined by 
the  Kolmogorov-Smirnov test. Correlational relationships between 
assays and between variables were investigated using the Pearson’s 
correlation coefficient, with significance adjusted to 0.01 level to 
account for multiple statistical testing. Differences between pre- and 
post-race levels for continuously distributed data were tested for sig-
nificance with a Repeated Measures ANOVA.
Results
Participant demographics and exercise 
parameters
Table 1 provides basic demographic and exercise char-
acteristics of the participants who completed the mara-
thon, with whom adequate serum sample volumes were 
 available at baseline and post-marathon (n = 69; 55 males, 
14 females). No PVCs were observed from pre- to post- 
marathon (mean±SD: 0.7%±8.1%), but because some 
participants exhibited individual changes (range: −12% 
to 19.9%), we included PVCs in secondary analyses, 
described later.
Effects of marathon exercise on serum 
creatinine
Displayed in Figure 1 are the observed changes in creatinine 
following marathon exercise. As anticipated, Repeated 
Measures ANOVA revealed that marathon exercise 
Table 1: Mean±SD (100% range) demographics and marathon data 
for the n = 69 participants enrolled in this study.
Demographics and marathon data   Mean±SD  100% range
Age, years   44.5±8.2  26–59
Body mass index, kg/m2   23.0±2.3  16.3–29.0
Number of completed marathons   8.51±16.8  0–102
Average heart rate during marathon, 
beats/min
  160.4±9.4  136–178
Average exercise intensity, % heart 
rate max
  90.6±5.0  76.1–100.0
Marathon speed, km/h   11.4±1.4  8.5–15.0
Finish time, min   225.4±26.3  169–298
220
200
180
160
140
120
100
80
60
40
Pre-marathon
Se
ru
m
 c
re
at
in
in
e,
 m
m
ol
/L
Post-marathon
Figure 1: Median (10th, 25th, 75th, 90th percentiles±outliers) 
serum creatinine levels before and immediately after the marathon 
(n = 60 participants).
*Indicates significant difference (p < 0.001) between pre- and post-
marathon. This finding is maintained after controlling for plasma 
volume changes during exercise (n = 39; p = 0.002).
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‘gaps’ [1]. These participants were thus, for data continu-
ity, excluded from any further serology analyses. Despite 
apparently normal creatinine and serum immunoglobulin 
(IgG, IgM and IgA) levels, one of the nine participants with 
an abnormal FLC ratio had elevated κ FLC (start: 66.2 mg/L; 
finish: 71.06 mg/L) and λ FLC (start: 25.6  mg/L; finish: 
23.9 mg/L) levels by Freelite® and was thus excluded on 
the grounds of abnormal absolute FLC levels. The remain-
ing five of nine participants with abnormal FLC ratios by 
Freelite® were subsequently tested by immunofixation 
electrophoresis; none had detectable paraproteins indica-
tive of plasma cell dyscrasias. However, unable to exclude 
light chain only MGUS, we conservatively excluded these 
participants from further serology analyses. Thus, a total 
of 60 participants with normal absolute κ and λ FLC 
levels, and a normal FLC ratio, were included in subse-
quent final serology analyses. We also confirmed that all 
60 patients had an FLC ratio within the expected 100% 
reference range of the mAb assay, as previously cited [11]. 
Finally, to ensure the mAb assay and Freelite® quantified 
FLC in a similar manner, we affirmed that they correlated 
well at baseline for κ FLC (R2 = 0.692; p < 0.001; n = 60), 
λ FLC (R2 = 0.507; p < 0.001; n = 60), ∑FLC (R2 = 0.653; p < 0.001; 
n = 60), and FLC ratio (R2 = 0.534; p < 0.001; n = 60), support-
ing a prior report [11].
Next, we assessed whether demographic or physi-
ological characteristics, reported in Table 1, were asso-
ciated with resting FLC levels. Using results generated 
from Freelite® and the mAb assay, we found no signifi-
cant associations between ∑FLC and age or BMI. Used 
as a proxy measure of physical fitness, we found that 
average exercise intensity and average heart rate were 
not associated with ∑FLC, and neither was marathon 
speed or finish time (data not shown). Eight partici-
pants reported hypercholesterolemia, but ∑FLC levels in 
these participants were not different to the other partici-
pants before or after the marathon. Finally, we assessed 
whether analgesics taken on the day of the marathon 
affected FLC levels. Five participants reported taking 
analgesics (n = 3 paracetamol; n = 2 paracetamol and ibu-
profen), but these did not affect ∑FLC levels before or 
after the marathon.
Effects of marathon running on serum FLC 
levels
Illustrated in Figure 2 are the absolute κ FLC, λ FLC and 
∑FLC levels before and after the marathon, measured on 
both the mAb assay and Freelite®, respectively. Repeated 
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Figure 2: Median (10th, 25th, 75th, 90th percentiles) serum κ FLC, λ 
FLC and ∑FLC, measured by Freelite® and the mAb assay before and 
immediately after a marathon (n = 60 participants).
*Indicates significant differences maintained during statistical 
analyses after controlling for plasma volume changes occurring 
during exercise (n = 39, p < 0.05).
measures ANOVA indicated that both assays detected 
a significant increase in κ FLC after the marathon (mAb 
assay: F(1, 59) = 28.244, p < 0.001; Freelite®: F(1, 59) = 9.344, 
p = 0.003), which was maintained upon inclusion of 
plasma volume as a covariate (mAb assay: F(1, 38) = 7.214, 
p = 0.011; Freelite®: F(1, 38) = 7.744, p = 0.008). Furthermore, 
the percentage change in κ FLC correlated positively with 
percentage change in creatinine (mAb assay: R2 = 0.631; 
p < 0.001; Freelite®: R2 = 0.716; p < 0.001; both n = 60), as 
well as average exercise intensity (mAb assay: R2 = 0.361; 
p = 0.010; Freelite®: R2 = 0.342; p = 0.015; both n = 50), and 
average heart rate using results from the mAb assay (mAb 
assay: R2 = 0.347; p = 0.014) but not Freelite® (R2 = 0.237; 
p = 0.098 [NS]; both n = 50); finish time and marathon 
speed showed no associations with κ FLC changes.
Figure 2 displays λ FLC levels before and after mara-
thon running. With PVCs included as a covariate, Repeated 
Measures ANOVA revealed no significant changes after 
exercise, as determined by mAb assay and Freelite® (both 
p > 0.05). Thus, with PVCs taken into account, our results 
indicated that marathon exercise increased κ FLC, but not 
λ FLC levels.
Also illustrated in Figure 2 are the effects of mara-
thon exercise on ∑FLC levels. Repeated Measures ANOVA 
revealed that ∑FLC levels increased significantly after 
exercise as determined on the mAb assay (F(1, 59) = 33.976, 
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after the marathon. This finding was maintained when 
accounting for plasma volume shifts (IgG: F(1, 37) = 14.710, 
p < 0.001; IgA: F(1, 37) = 16.598, p < 0.001).
p = 0.001), but not Freelite® (p = 0.068); the mAb assay 
findings were maintained upon inclusion of PVCs as a 
covariate (F(1, 38) = 6.240, p = 0.017) and correlated positively 
with percentage change in serum creatinine (R2 = 0.698; 
p < 0.001; n = 60).
Illustrated in Figure 3 are the effects of marathon 
running on the FLC ratio, measured by both the Free-
lite® and mAb assays, respectively. Following exercise, 
we found a significant increase in the FLC ratio on Free-
lite® (F(1, 59) = 40.207, p < 0.001), but not on the mAb assay 
(p = 0.062). Interestingly, eight (13%) participants had an 
FLC ratio above the normal reference range on Freelite® 
after the marathon.
Effects of marathon running on serum 
 immunoglobulin levels
Figure 4 displays the effect of marathon running on 
total serum levels of IgG, IgA, and IgM. We found a sig-
nificant increase in IgG (F(1, 59) = 22.790, p < 0.001) and IgA 
(F(1, 59) = 7.319, p = 0.009) but not IgM (p > 0.05) immediately 
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mAb assay 1.08±0.30 1.11±0.29
Freelite 1.03±0.27 1.17±0.35
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Figure 3: Serum FLC ratio per participant (n = 60) observed before and after marathon running, as measured on the mAb assay (left) and 
Freelite® (right).
When controlling for plasma volume changes occurring during exercise, no significant differences were observed on either assay between 
baseline and post-exercise (p > 0.05). However, 8 (13%) of participants developed an FLC ratio above the normal Freelite® reference range 
(long dash = upper reference range, short dash = lower reference range) upon exercise cessation when measured by Freelite®. Pearson’s cor-
relation coefficients revealed that exercise introduced greater change to the FLC ratio on Freelite® compared to the mAb assay.
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Figure 4: Median (10th, 25th, 75th, 90th percentiles) levels of 
serum IgA, IgM and IgG, measured before and immediately after a 
marathon (n = 60 participants).
*Indicates significant differences maintained during statistical 
analyses when controlling for plasma volume changes occurring 
during exercise (n = 39, p < 0.05).
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Discussion
Using two different FLC assays, we found that κ FLC levels in 
healthy participants were increased immediately after mar-
athon exercise. Although the increase in κ FLC was modest 
(median to maximum increase: 7%–56%  [Freelite®], 11%–
52% [mAb assay]), and no changes to λ FLC were observed, 
we found that 13% of participants developed an abnormal 
FLC ratio upon exercise cessation. This is the first study to 
report changes to serum FLC levels in healthy participants 
following intensive aerobic exercise.
Generally, polyclonal serum FLCs can be elevated by 
two principle mechanisms: either immune stimulation or 
renal impairment. We are unable to exclude the possibil-
ity that the minor increases to FLCs – as well as IgG and 
IgA – seen in our study, reflects exercise-induced immune 
stimulation, or redistribution of immunoglobulins from 
peripheral sites during exercise. We previously demon-
strated that long duration walking exercise did not signifi-
cantly affect FLC levels [9]. The low intensity nature of the 
exercise task may not have elicited the pro-inflammatory 
effects typically seen in response to more intensive exer-
cise modalities [16].
Marathon running may also induce acute and tran-
sient renal impairment [8]. In the aforementioned study 
it was shown that serum creatinine levels increased into 
territory normally diagnostic of kidney injury [7]. In our 
study, we report a large increase in serum creatinine 
[post-marathon median (range): 122 (72–198) mmol/L], 
which culminated in 42% of participants exhibiting 
creatinine levels indicative of kidney injury [14]. We 
also found that change in κ FLC levels positively corre-
lated with increases in serum creatinine. This gave rise 
to an increase in the FLC ratio on the Freelite® assay, a 
phenomenon previously reported in kidney disease [7]. 
Interestingly, elevations to the FLC ratio in patients with 
renal impairment is an apparent feature of Freelite®, but 
is not replicated on mAb-based ‘N Latex’ [17] or ‘Seralite’ 
assays [18]. Without the availability of an internation-
ally accepted FLC reference method it remains unknown 
whether decreased kidney function affects the FLC ratio 
in serum. We also acknowledge that creatinine is not a 
gold standard biomarker for confirming renal impair-
ment, and in this case is further limited by acute eleva-
tions in creatinine released from exercising muscle. 
However, McCullough et  al. [8] showed that serum cre-
atinine levels were positively correlated with cystatin-
C post-exercise, and, kidney injury was confirmed in 
these participants via five-fold elevations to neutrophil 
gelatinase- associated lipocalin (NGAL) and a minor rise 
to kidney injury molecule-1 (KIM-1).
FLCs are biologically active molecules that can, under 
certain circumstances, induce renal inflammation and 
nephrotoxicity [4, 7]. The results from our study showed 
that an acutely strenuous bout of exercise induced only 
minor changes to absolute serum FLC levels, and thus, the 
effect on kidney function in healthy individuals is likely to 
be negligible. This study was unable to assess the effects 
of longer term exercise participation on FLC levels. Exer-
cise training has been shown to reduce pro-inflammatory 
mediators, in both healthy and clinical populations [19], 
and, as such, future studies should investigate whether 
exercise training affects FLC levels. Importantly, exer-
cise training has been shown to have benefits in chronic 
kidney disease patients [20–22], but as yet, it remains 
unknown whether this leads to a change in the levels of 
nephrotoxic FLCs.
In conclusion, we found κ FLC levels showed a 
minor increase after marathon running leading to an 
increase in the FLC ratio on the Freelite® assay; the FLC 
ratio was outside the normal reference range in 13% of 
participants at exercise cessation. As FLC are cleared by 
the kidneys, these findings may support prior reports 
showing acute and transient reductions in the renal 
function of healthy participants immediately after mara-
thon distance running.
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